СHRONIC MIGRAIN. CLINICAL OBSERVATION. OVERVIEW: CLINIC AND TREATMTNT
Keywords:
chronic migraine, headache, medication overuse headache, migraineAbstract
Significant advances in our understanding of chronic migraine pathophysiology have been made over the last years. Neuroimaging findings support the view that migraine is a spectrum disorder, with clinical and pathophysiological features that can progress over time. Chronic and episodic migraine share similar functional and structural alterations in brain regions implicated in the generation of the migraine attack and in pain processing. However, chronic migraine patients experience a more pronounced dysfunction of the pain inhibitory network and an increased sensitization of the central pain pathways, which might explain the higher susceptibility to migraine attacks. In this new era of migraine treatments, a better understanding of chronic migraine pathophysiology will pave the way for the development of new improved treatments specifically designed for chronic migraine patients
References
Артеменко А.Р., Куренков А.Л., Беломестова К.В. Классификация, диагностика и лечение хронической мигрени: обзор новых данных. Журнал неврологии и психиатрии им. С.С. Корсакова. 2013;113(11):91–6.
Артеменко А.Р., Куренков А.Л. Хроническая мигрень. М.: АБВ-пресс, 2012. 488 с.
Табеева Г.Р. Головная боль . Руководство дяя врачей. 2018 «Геотар- Медиа», 293 стр.
Сергеев А.В., Мещерина М.И., Табеева Г.Р. Головная боль связанная с избыточным приемом анальгетиков. Эпилепсияипароксизмальноесостояния. 2011, 3, 3, 21-28.
BigalM.E., LiptonR.B. Modifiablerisk factors for migraine progression. Headache 2006;46:1334–43.
Bigal M.E., Ferrari M., Silberstein S.D. et al. Migraine in the triptan era: lessons from epidemiology, pathophysiology, and clinical science. Headache 2009;49:21–33.
Buse D.C., Manack A.N., Fanning K.M. et al. Chronic migraine prevalence, disability, andsociodemographic factors: results from the American Migraine Prevalence and Prevention Study. Headache 2012;52(1):3–17.
Bigal ME, Serrano D, Buse D, Scher A, Stewart WF, Lipton RB. Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache. 2008;48:1157–1168.
Blumenfeld A.M., Schim J.D., Chippendale T.J. Botulinum toxin type Aanddivalproex sodium for prophylactic treatment of episodic or chronic migraine.
Headache 2008;48:210–20.
Blumenfeld, S.D. Silberstein, D.W. Dodick, S.K. Aurora, C.C. Turkel, W.J. Binder .Method of injection of onabotulinumtoxinA for chronic migraine: a safe, well-tolerated, and effective treatment paradigm based on the PREEMPT clinical program Headache, 50 (2010), pp. 1406-1418
Buse DC, Manack AN, Fanning KM et al. Chronic migraine prevalence, disability, and sociodemographic factors: results from the American Migraine Prevalence and Prevention Study. Headache. 2012;52:1456–1470.
.Buse DC, Loder EW, Gorman JA et al. Sex differences in prevalence, symptoms, and other features of migraine, probable migraine and other severe headache: results of the American Migraine Prevalence and Prevention Study. Headache.2013;53:1278–1299.
Diener H., Dodick D., Goadsby P. Chronic migraine—classification, characteristics and treatment.Nature Reviews Neurology . 2012. 8, 162–171..
Goadsby P. The diagnosis and treatment of chronic migraine.Ther Adv Chronic Dis.2015 . 6(3): 115–123
Lipton R.B. Chronic migraine, classification, differential diagnosis, and epidemiology. Headache 2011;51:77–83.
Lipton RB, Buse DC, Fanning KM, Serrano D, Reed ML. Suboptimal acute treatment of episodic migraine (EM) is associated with an increased risk of progression to chronic migraine (CM): results of the American Migraine Prevalence and Prevention (AMPP) Study. (LB02) Cephalalgia. 2013;33:954–992.
Lipton R.B., Serrano D., Holland S. et al. Barriers to the diagnosis and treatment of migraine: effects of sex, income, and headache features. Headache 2013;53(1):
–92.
Mathew N.T. The prophylactic treatment of chronic daily headache. Headache
;46:1552–64.
Negro A., Rocchietti-March M., Fiorillo M. et al. Chronic migraine: current concepts and ongoing treatments. Eur Rev MedPharmacolSci 2011;15:1401–20.
Olesen J., Goadsby P., Ramadan N. The Headaches. Philadelphia: 2006.
OlesenJ.,Bousser M., First D., et al. New appendix criteria open for a broader concept of chronic migraine. Cephalgia2006 ,26,742-746.
Sher A., Stewart W., Lipton R. Factor associated wich the onset and remission of chronic daily headache in a population-based study. Pain.2003,106,181-189.
Silberstein S., Tfelt-Hansen P., Dodick D.W. et al. Guidelines for controlled trials of prophylactic treatment of chronic migraine in adults.Cephalalgia 2008;28:484–95.
Silberstein SD, Lipton RB, Dodick DW. Operational diagnostic criteria for chronic migraine: expert opinion. Headache. 2014;54:1258–1266.
Silberstein S. Transformd and chrnicmigraine.In : Chronic Dayly Headache. London LBC Decker ,inc. Hamilton,2005,22-56.
Shulte L., May A. Chronic migraine: risk factors, mechanisms and treatment. Nature Reviews Neurology . 2016, 12, 455–464.
